BPC-157: What the Published Evidence Contains

BPC-157 has a large reputation online and a small evidence base in people. This article counts what has actually been published, describes how each human study was designed, explains why those designs cannot settle the question, and sets out the positions of the FDA and the anti-doping authorities.

What it is

BPC-157 is a chain of 15 amino acids, a pentadecapeptide. The letters stand for body protection compound. A 2025 systematic review describes it as a naturally occurring gastric peptide, and the research papers on it go back to 1993. For most of that time it has been studied as an experimental compound in animal models of injury to the gut, tendons, ligaments, muscle and bone.

It is not approved as a medicine by the FDA or by any other health authority, according to the US Anti-Doping Agency. That is the starting point for everything below: no regulator has weighed its benefits against its risks as a medicine, so the useful question is what the published research can and cannot support.

Counting the evidence

In 2025, researchers published a systematic review of BPC-157 in orthopaedic sports medicine in HSS Journal. They searched three major databases from their start to June 2024, and two reviewers screened every article in three rounds.

The review reports that in preclinical models BPC-157 improved functional, structural and biomechanical measures after injuries to muscle, tendon, ligament and bone, and that it appears to act on pathways involved in growth hormone receptor expression, cell growth and the formation of new blood vessels. According to the review it is broken down in the liver, has a half-life of under 30 minutes, and is cleared by the kidneys.

The review describes the studies it found as level IV and level V evidence, the two lowest levels on the usual scale. Level V covers mechanism studies and expert opinion; level IV covers case series without a control group. Its authors concluded that these studies suggest promise for musculoskeletal injuries, that adverse effects are possible because of unregulated manufacturing, contamination or unknown clinical safety, and they found no clinical safety data at all.

The human reports

Three small human reports have been published. All three come from the same lead author, all three appeared in the journal Alternative Therapies in Health and Medicine, and none had a control group.

The knee pain report is the single clinical study counted by the 2025 review. The interstitial cystitis pilot involved women aged 39 to 76 whose symptoms had not responded to an approved treatment; the peptide was given during cystoscopy and was made by a compounding pharmacy. In the intravenous pilot, blood tests and vital signs were taken ahead of each infusion and again the next day. Its authors wrote that the infusions were well tolerated and that the results showed the safety of BPC-157 in humans, while also calling for future studies to confirm it. The next section explains why two people cannot establish that.

Why these studies cannot settle the question

None of the three reports is dishonest for being small. Pilot studies exist to decide whether a proper trial is worth running. The problem is that small uncontrolled studies are routinely read as if they were proper trials.

• No control group. Pain and bladder symptoms vary over time, and people often seek treatment when symptoms are at their worst, so many improve whatever is done. Without a comparison group, that improvement cannot be separated from any effect of the peptide.
• No blinding. Both participants and investigators knew what was given. Expectation changes how symptoms are reported, especially on questionnaires.
• Tiny numbers. Twelve people cannot show whether a benefit is real or estimate how large it is, and two people cannot show that something is safe.
• One research group. Findings become reliable when independent groups repeat them.

A 2026 review in Sports Medicine, covering BPC-157 alongside other unapproved peptides such as TB-500, CJC-1295, ipamorelin and MOTS-c, reached a similar view. Many of these compounds look favourable in animal models, rigorous human safety data are scarce, there is potential for serious harm, and the authors discuss the placebo effect as a driver of the benefits people report, amplified by social media.

What "no adverse events" means in a small study

The safety point deserves numbers. Imagine a side effect that affects 1 person in every 100. In a study of 12 people, the chance of seeing no cases at all is 88.6%. In a study of 2 people it is 98.0%. A report of "no adverse events" in a study that small is therefore what you would expect even if the side effect were real.

That rule of thumb, published in 1983 as the rule of three, puts it another way. When none of 12 people has a particular adverse event, the true rate could still be as high as about one in four. With 2 people, the data rule out almost nothing. This is why phase 3 trials enrol hundreds or thousands of people, and why the FDA describes phase 3 as the stage for monitoring adverse reactions.

What regulators and sport authorities say

The FDA

The FDA keeps a list of bulk substances nominated for use in compounding that may present significant safety risks. On the version current as of 22 April 2026, the entry for BPC-157 makes three points. Compounded products containing it may pose a risk of immune reactions for some routes of administration. They may involve complexities with peptide-related impurities and with characterising the active ingredient. And the FDA has identified no, or limited, safety information for the proposed routes, so it lacks sufficient information to know whether BPC-157 would cause harm when given to humans. BPC-157 had been placed in category 2 on that list, and its nomination for compounding was later withdrawn by the nominators.

Anti-doping authorities

BPC-157 is prohibited in sport at all times under section S0 of the World Anti-Doping Agency's Prohibited List, the category for pharmacological substances with no current approval by any government health authority for human therapeutic use. The US Anti-Doping Agency notes that the claims made for it on websites are not supported by the medical literature or by medical associations. The 2025 systematic review makes the same practical point for doctors: athletes should be advised to check the rules of their own organisations.

Safety: what is known and what is not

• Known from animals: preclinical safety studies reported no adverse effects across several organ systems, according to the 2025 review.
• Not known in people: the review found no clinical safety data. The two pilot reports that mention safety involved 12 and 2 people.
• Product quality: the review warns that adverse effects are possible from unregulated manufacturing and contamination, and the FDA's concerns centre on immune reactions and impurities.
• Unknown long-term effects: no study has followed people over months or years in a controlled way.

What would settle it

The path is the same one every approved peptide has followed. Controlled, blinded trials with outcomes registered in advance, run by more than one research group, large enough to detect harms that affect one person in a hundred, and using a product whose identity, purity, impurities, sterility and endotoxin levels are characterised and reported. Until that evidence exists, the honest summary of BPC-157 in people is short: not known.